RESUMEN

New York City has emerged as one of the epicenters of the SARS-COV-2 pandemic, with the Bronx being disproportionately affected. This novel coronavirus has caused significant respiratory manifestations raising the concern for development of acute chest syndrome (ACS) in patients with sickle cell disease (SCD). We report a series of pediatric SCD SARS-COV-2-positive patients admitted with ACS. SARS-COV-2-positive SCD patients, who did not develop ACS, were the comparison group. Hydroxyurea use (P-value = .02) and lower absolute monocyte counts (P-value = .04) were noted in patients who did not develop ACS. These preliminary findings need to be further evaluated in larger cohorts.

Asunto(s)

Síndrome Torácico Agudo/complicaciones , Anemia de Células Falciformes/complicaciones , COVID-19/complicaciones , Síndrome Torácico Agudo/diagnóstico , Síndrome Torácico Agudo/tratamiento farmacológico , Adolescente , Anemia de Células Falciformes/tratamiento farmacológico , Antibacterianos/uso terapéutico , Antidrepanocíticos/uso terapéutico , COVID-19/diagnóstico , Prueba de COVID-19 , Niño , Doxiciclina/uso terapéutico , Femenino , Hospitales Urbanos , Humanos , Hidroxiurea/uso terapéutico , Masculino , Ciudad de Nueva York , Reacción en Cadena de la Polimerasa , SARS-CoV-2 , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Adulto Joven , Tratamiento Farmacológico de COVID-19